• 1
    Yoshida S, Yamaguchi H, Saito D, Kido M. Endoscopic diagnosis; Latest trends; In NishiM, IchikawaH, NakajimaT, TaharaE (eds) Gastric Cancer. Pp 24662, Tokyo, Springer, 1993.
  • 2
    Ono H. Endoscopic submucosal dissection for early gastric cancer. Chin J Dig Dis 2005; 6(3): 11921.
  • 3
    Nishino Y, Suzuki Y, Ohmori K et al. Cancer incidence profiles in the Miyagi Cohort Study. J Epidmiol 2004; (Suppl 1): S711.
  • 4
    Ajiki W, Tsukuma H, Oshima A. Trends in cancer incidence and survival in Osaka. Cancer Mortality and Morbidity Statistics: Japan and the World-2004, TajimaK, KuroishiT, OshimaA (ed), Gann Monograph on Cancer Research, 51: pp 13763. Japan Sci Soc Press, Tokyo, 2004.
  • 5
    Lambert R, Guiloux A, Oshima A et al. Incidence and mortality from stomach cancer in Japan, Slovenia and the USA. Int J Cancer 2002; 97: 8118.
  • 6
    Sano T, Sasako M, Yamamoto S et al. Gastric cancer surgery: Morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy-Japan Clinical Oncology Group Study 9501. J Clin Oncol 2004; 22: 276773.
  • 7
    Moiseyenko VM, Ajani J, Tjulandin SA et al. Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). J Clin Oncol 2005; 23: 308s (Abstr 4002).
  • 8
    Cullinan SA, MOertel CG, Wieand HS et al. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. J Clin Oncol 1994; 12: 41216.
  • 9
    Kim NK, Park YS, Heo DS et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-flluorouracil, doxorubicin and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993; 71: 381318.
  • 10
    Ohtsu A, Shimada Y, Shirao K et al. Randomized phase III trial fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable advanced gastric cancer. The Japan Clinical Oncology Group study (JCOG9205). J Clin Oncol 2003; 21: 549.